Immuno Vaccine Inc (IMMVF) 0.4468 $IMMVF
Immunovaccine Provides Corporate Update and Announces Second Quarter 2016 Financial Results
Marketwired - Tue Aug 09, 4:06PM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - Aug 9, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "Company"
(TSX:IMV)(OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today provided a corporate update and announced financial results for the second quarter ended June 30, 2016.
IMV.TO: 0.58 (unch)
Immunovaccine Announces Preclinical Collaboration for DepoVax(TM)-Based Malaria Vaccine
Marketwire Canada - Thu Jun 02, 6:06AM CDT
Initial Study Conducted With The University of Edinburgh to Examine Vaccine Candidate's Effects on Malaria Parasites Linked to Most Severe Form of the Disease
IMV.TO: 0.58 (unch)
Immunovaccine Announces Financial Results for Quarter Ended March 31, 2016
Marketwire Canada - Tue May 10, 4:06PM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 10, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "Company" (TSX:IMV) (OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2016.
IMV.TO: 0.58 (unch), INCY: 81.98 (+5.87), LDOS: 40.35 (+0.86)
Immunovaccine Launches DPX-NEO Program to Develop Patient-Specific Neoepitope Immunotherapies
Marketwired - Thu May 05, 6:06AM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 5, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced the launch of its DPX-NEO program to develop neoepitope immunotherapies to further expand the immuno-oncology applications for its DepoVax™-based vaccines. As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and anti-tumor activity of patient-specific neoepitopes.
IMV.TO: 0.58 (unch)
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Thu Apr 28, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 3, 2016 at 3:00 p.m. Eastern Time.
IMV.TO: 0.58 (unch)
New Preclinical Study Shows Immunovaccine's DepoVax(TM)-Based Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors
Marketwired - Wed Apr 20, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016. The investigators' findings showed that a combination immunotherapy using a DepoVax(TM)-based vaccine could enhance the anti-tumor effects of a PD-1 blockade, controlling growth in advanced HPV-expressing tumors in animal models.
IMV.TO: 0.58 (unch)
Immunovaccine Elects Medicago CEO Andy Sheldon as Board Chairman; Reports Results of the Annual General Meeting (AGM)
Marketwired - Fri Apr 15, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV) (OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today elected Andrew Sheldon as chairman of its board of directors. Mr. Sheldon, who currently serves as President and CEO of Medicago, joined the board after the company's annual and special meeting of shareholders. Newly named Chief Executive Officer Frederic Ors was also elected to the board.
IMV.TO: 0.58 (unch)
Immunovaccine Names Frederic Ors Chief Executive Officer; Andy Sheldon, Medicago CEO, to Join Board of Directors
Marketwired - Wed Apr 13, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that Frederic Ors has been appointed Chief Executive Officer. He and Andy Sheldon, President and CEO of Medicago, will be nominated to the board of directors at the Company's AGM on April 14, and the Board will recommend their election.
IMV.TO: 0.58 (unch)
Immunovaccine to Present New Pre-Clinical Data at the 2016 AACR Annual Meeting
Marketwired - Mon Apr 11, 4:05PM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that new pre-clinical data on DPX(TM)-based cancer vaccines will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, which be held in New Orleans, Louisiana, April 16-20, 2016.
IMV.TO: 0.58 (unch)
Immunovaccine and Leidos Join Forces to Develop a Zika Virus Vaccine Candidate
Marketwired - Thu Apr 07, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, and Leidos (NYSE: LDOS), a health, national security and infrastructure solutions company, today announced they will collaborate on developing a vaccine against the mosquito-borne Zika virus and infection, which may be linked to neurological birth defects.
IMV.TO: 0.58 (unch), LDOS: 40.35 (+0.86)
Immunovaccine Announces 2015 Year-End Results
Marketwired - Tue Mar 29, 4:06PM CDT
Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced its financial and operational results for the year ended December 31, 2015.
IMV.TO: 0.58 (unch), INCY: 81.98 (+5.87)
Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 7.07 (+0.23), FOMX: 8.80 (+0.10), GNCA: 5.24 (+0.06), NNVC: 1.65 (-0.02)
Immunovaccine Provides Corporate Update and Announces Second Quarter 2016 Financial Results
Marketwired - Tue Aug 09, 4:06PM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - Aug 9, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "Company"
(TSX:IMV)(OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today provided a corporate update and announced financial results for the second quarter ended June 30, 2016. IMV.TO: 0.58 (unch)
Immunovaccine Announces Preclinical Collaboration for DepoVax(TM)-Based Malaria Vaccine
Marketwire Canada - Thu Jun 02, 6:06AM CDT
Initial Study Conducted With The University of Edinburgh to Examine Vaccine Candidate's Effects on Malaria Parasites Linked to Most Severe Form of the Disease
IMV.TO: 0.58 (unch)
Immunovaccine Announces Financial Results for Quarter Ended March 31, 2016
Marketwire Canada - Tue May 10, 4:06PM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 10, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "Company"
(TSX:IMV) (OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2016. IMV.TO: 0.58 (unch), INCY: 81.98 (+5.87), LDOS: 40.35 (+0.86)
Immunovaccine Launches DPX-NEO Program to Develop Patient-Specific Neoepitope Immunotherapies
Marketwired - Thu May 05, 6:06AM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 5, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company"
(TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced the launch of its DPX-NEO program to develop neoepitope immunotherapies to further expand the immuno-oncology applications for its DepoVax™-based vaccines. As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and anti-tumor activity of patient-specific neoepitopes. IMV.TO: 0.58 (unch)
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Thu Apr 28, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"
(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 3, 2016 at 3:00 p.m. Eastern Time. IMV.TO: 0.58 (unch)
New Preclinical Study Shows Immunovaccine's DepoVax(TM)-Based Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors
Marketwired - Wed Apr 20, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"
(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016. The investigators' findings showed that a combination immunotherapy using a DepoVax(TM)-based vaccine could enhance the anti-tumor effects of a PD-1 blockade, controlling growth in advanced HPV-expressing tumors in animal models. IMV.TO: 0.58 (unch)
Immunovaccine Elects Medicago CEO Andy Sheldon as Board Chairman; Reports Results of the Annual General Meeting (AGM)
Marketwired - Fri Apr 15, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"
(TSX: IMV) (OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today elected Andrew Sheldon as chairman of its board of directors. Mr. Sheldon, who currently serves as President and CEO of Medicago, joined the board after the company's annual and special meeting of shareholders. Newly named Chief Executive Officer Frederic Ors was also elected to the board. IMV.TO: 0.58 (unch)
Immunovaccine Names Frederic Ors Chief Executive Officer; Andy Sheldon, Medicago CEO, to Join Board of Directors
Marketwired - Wed Apr 13, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"
(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that Frederic Ors has been appointed Chief Executive Officer. He and Andy Sheldon, President and CEO of Medicago, will be nominated to the board of directors at the Company's AGM on April 14, and the Board will recommend their election. IMV.TO: 0.58 (unch)
Immunovaccine to Present New Pre-Clinical Data at the 2016 AACR Annual Meeting
Marketwired - Mon Apr 11, 4:05PM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"
(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that new pre-clinical data on DPX(TM)-based cancer vaccines will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, which be held in New Orleans, Louisiana, April 16-20, 2016. IMV.TO: 0.58 (unch)
Immunovaccine and Leidos Join Forces to Develop a Zika Virus Vaccine Candidate
Marketwired - Thu Apr 07, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company"
(TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, and Leidos (NYSE: LDOS), a health, national security and infrastructure solutions company, today announced they will collaborate on developing a vaccine against the mosquito-borne Zika virus and infection, which may be linked to neurological birth defects. IMV.TO: 0.58 (unch), LDOS: 40.35 (+0.86)
Immunovaccine Announces 2015 Year-End Results
Marketwired - Tue Mar 29, 4:06PM CDT
Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced its financial and operational results for the year ended December 31, 2015.
IMV.TO: 0.58 (unch), INCY: 81.98 (+5.87)
Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 7.07 (+0.23), FOMX: 8.80 (+0.10), GNCA: 5.24 (+0.06), NNVC: 1.65 (-0.02)
